Q/C Technologies, Inc.
QCLS- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001321834
No open-market purchases or sales by Q/C Technologies, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.87M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Q/C Technologies, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Of which not filed for Q1 2024 | Q1 2024 | Change |
|---|---|---|---|---|
| Holders | 50 | 1 | 20 | −29 |
| SharesConverted for a 1-for-30 split | 211.5K | 1.00K | 917.9K | +707.3K (+336.0%) |
| Value | $1.64M | $7.77K | $1.38M | −$252.9K (−15.5%) |
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Q/C Technologies, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| WR Wealth Planners, LLC | 34 | $81 | 0.00% |
Sold out (30)
Institutions that held Q/C Technologies, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
Not filed for Q1 2024 yet (1)
Institutions that held Q/C Technologies, Inc. at the end of Q4 2023 and haven't filed a 13F for Q1 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Bridgecreek Investment Management, LLC | 30,000 | $7.77K |